600422.SH
昆药集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.31
−2.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.8B | 6.6B | 8.4B | 8.4B | 8.3B |
| Cost of Revenue | 3.7B | 4.0B | 4.8B | 4.5B | 4.8B |
| Gross Profit | 2.1B | 2.5B | 3.7B | 3.9B | 3.4B |
| Operating Expenses | |||||
| R&D Expense | 95.5M | 102.5M | 106.8M | 94.2M | 69.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 375.9M | 378.6M | 371.2M | 343.1M | 379.1M |
| Selling & Marketing Expense | 1.6B | 1.7B | 2.2B | 2.6B | 2.4B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.2B | 2.3B | 2.8B | 3.2B | 3.0B |
| Cost and Expenses | 5.9B | 6.3B | 7.6B | 7.7B | 7.8B |
| Operating Income (EBIT) | 166.0M | 448.5M | 927.5M | 789.7M | 497.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 186.2M | 473.6M | 934.6M | 786.4M | 477.3M |
| Income Tax Expense | 25.5M | 54.5M | 183.3M | 143.7M | 91.8M |
| Bottom Line | |||||
| Net Income | 117.7M | 349.9M | 648.1M | 540.7M | 383.2M |
| Earnings from Cont. Ops | 160.7M | 419.1M | 751.2M | 642.7M | 385.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 117.7M | 349.9M | 648.1M | 540.7M | 383.2M |
| Per Share | |||||
| Basic EPS | CN¥0.15 | CN¥0.46 | CN¥0.86 | CN¥0.71 | CN¥0.51 |
| Diluted EPS | CN¥0.15 | CN¥0.46 | CN¥0.86 | CN¥0.71 | CN¥0.51 |
| Revenue Per Share | CN¥7.78 | CN¥8.64 | CN¥11.15 | CN¥11.07 | CN¥11.02 |
| Shares | |||||
| Basic Shares Outstanding | 746.2M | 760.7M | 753.6M | 761.6M | 751.3M |
| Diluted Shares Outstanding | 746.2M | 760.7M | 753.6M | 761.6M | 751.3M |
| Profitability Metrics | |||||
| EBITDA | — | 623.3M | 1.1B | 976.6M | 713.2M |
| D&A | — | 174.8M | 184.8M | 186.9M | 216.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026